Join to view full profile
Palazzo HealthCare Clinic12540 SW Eighth StMiami, FL 33184
Phone+1 305-705-6840
Dr. Gonzalez is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Jorge Gonzalez, based in Miami, FL and specializes in neurology with a subspecialty in neurorehabilitation. Dr. Gonzalez completed a fellowship in neuro rehabilitation and a residency in neurology after attending Universidad de Navarra Faculty of Medicine. Areas of expertise include general neurology, electroencephalography, trigeminal neuralgia, migraine, and Alzheimer's disease. Dr. Gonzalez authored a publication on mild traumatic brain injury and has participated in clinical trials evaluating treatments for psychosis associated with Alzheimer's disease. Recognized with CMS Meaningful Use Stage 1 and 2 Certifications across several systems from 2014 to 2017.
Education & Training
University of Miami Hospital and ClinicsFellowship, Neuro Rehabilitation , 1992 - 1993
Drexel University College of Medicine/Hahnemann University HospitalResidency, Neurology, 1988 - 1992
Universidad de Navarra Faculty of MedicineClass of 1984
Certifications & Licensure
FL State Medical License 1992 - 2027
OK State Medical License 1995 - 2026
PA State Medical License 1991 - 2026
IL State Medical License 1999 - 2017
IN State Medical License 1998 - 2017
KS State Medical License 2015 - 2017
TX State Medical License 2012 - 2017
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification P2 Sentinel, Cerner Corporation, 2014, 2017
- CMS Meaningful Use Stage 1 Certification Centricity Practice Solution, GE Healthcare, 2014, 2017
- CMS Meaningful Use Stage 2 Certification PowerChart (Clinical), Cerner Corporation, 2014, 2017
Clinical Trials
- Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) Start of enrollment: 2023 Jul 11
- A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) Start of enrollment: 2024 Sep 26
Publications & Presentations
Books/Book Chapters
Research History
- Principal InvestigatorEfficacy of KarXT for the treatment of psychosis in AD Long term safety and tolerability of KarXT in subjects with psychosis in AD2023 - 2026
Professional Memberships
- Member
Other Languages
- French, Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
